- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.01. | BofA Securities initiates coverage on Inhibikase stock with Buy rating | 5 | Investing.com | ||
| 29.12.25 | Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path | 3 | Investing.com | ||
| 29.12.25 | Jefferies bekräftigt Kaufempfehlung für Inhibikase-Aktie wegen beschleunigtem FDA-Verfahren | 3 | Investing.com Deutsch | ||
| 26.12.25 | Inhibikase: H.C. Wainwright startet Coverage mit "Buy" und 385 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.12.25 | H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating | 3 | Investing.com | ||
| 19.12.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share | 1 | Seeking Alpha | ||
| 21.11.25 | Inhibikase Therapeutics prices $100 million public offering | 1 | Investing.com | ||
| 21.11.25 | Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 20.11.25 | Inhibikase Therapeutics announces proposed public offering and pre-funded warrants | 1 | Seeking Alpha | ||
| 20.11.25 | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | 160 | GlobeNewswire (Europe) | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen | |
| 14.11.25 | Inhibikase Therapeutics GAAP EPS of -$0.13 | 2 | Seeking Alpha | ||
| 14.11.25 | Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity | 907 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 14.11.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.08.25 | Inhibikase taps commercial chief from Pfizer, Gilead to pave the way for PAH launch | 31 | FiercePharma | ||
| 19.08.25 | Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | 400 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 14.08.25 | Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | 255 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 27.03.25 | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 520 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen | |
| 18.02.25 | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 276 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 185,20 | -0,43 % | AbbVie sues US health agency over Botox price controls | ||
| TEVA | 28,900 | 0,00 % | GSK, Teva quietly settle Coreg 'skinny label' dispute after long legal back-and-forth | ||
| EYEPOINT | 11,225 | +3,74 % | RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline | ||
| ORGANIGRAM GLOBAL | 1,110 | -0,89 % | Organigram reports revenue boost in Q1 | ||
| QUANTUM BIOPHARMA | 3,400 | +5,59 % | Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) | TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 55,50 | -0,89 % | Nektar Therapeutics: New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing | 71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively
Meaningful... ► Artikel lesen | |
| AMARIN | 12,200 | -3,94 % | Amarin Corporation plc: Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization | DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 137,80 | -1,61 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 | DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,525 | -2,35 % | Tabakaktie ohne Tabak und PayPal im Sandwich: Alan Galecki zu Altria, Zoom, Achieve Life Sciences, ABF und PayPal | ||
| SELLAS LIFE SCIENCES | 3,085 | +0,16 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 403,80 | -0,22 % | Suzhou Ribo Life Science Co., Ltd.: Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH | SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,334 | -6,70 % | XORTX Therapeutics Inc.: XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems | CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 60,90 | -1,39 % | BridgeBio shares slide amid report that Pfizer will withdraw Vyndamax EU patent | ||
| OPUS GENETICS | 2,750 | -0,72 % | Opus Genetics, Inc.: Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa | The trial is funded through Abu Dhabi's Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 29,400 | -0,68 % | Rigel Pharmaceuticals: Geht es 2026 noch höher? | Die Aktie von Rigel Pharmaceuticals hatten wir sharedealsPlus-Nutzern erstmals im Jahr 2022 ans Herz gelegt. Der Kurs konnte seitdem über 400% zulegen und auch unser September-Update mit Verweis auf... ► Artikel lesen |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.